1. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting, September 27–30, 2006, San Francisco.
2. Task Force on Antimicrobial Availability. Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews (Infectious Diseases Society of America, Alexandria, VA, July 2004). <
http://www.idsociety.org/pa/IDSA_Paper4_final_web.pdf
>
3. <
http://www.fda.gov/cder/guidance/#clinical%20antimicrobial
>
4. European Medicines Agency/Committee for Proprietary Medicinal Products. Note for Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (EMEA/CPMP, London, October 2004). <
http://www.emea.eu.int/pdfs/human/ewp/055895en.pdf
>
5. US Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for Industry for Special Protocol Assessment (FDA/CDER, Rockville, Maryland, 2002). <
http://www.fda.gov/cder/guidance/3764fnl.htm
>